Payment overview · 2025
General Payments
$1,031.30
53 reported records · 22 companies
Healthcare provider profile · identity verified
Ashish C Shah, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EDEN, NC · NPI 1730287020
Verified facts
What the public records show
CMS Open Payments records show Ashish C Shah, M.D. received $1,031.30 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $220.12 | 21.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.13 | 14.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.90 | 7.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.38 | 5.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.28 | 5.1% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $47.65 | 4.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $46.23 | 4.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.02 | 4.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.89 | 3.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.39 | 3.3% | 2 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.33 | 3.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.80 | 3.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $27.03 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.67 | 2.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $22.50 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.51 | 2.0% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.10 | 1.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.68 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.37 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.93 | 1.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.94 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,031.30 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $99.75 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $90.78 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $89.95 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $89.73 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $85.08 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $66.01 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.35 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.38 | 3 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $46.23 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 141 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 925 | 224 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 796 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 784 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 631 | 122 |
| Lisinopril | Lisinopril | 610 | 138 |
| Gabapentin | Gabapentin | 595 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 572 | 137 |
| Metformin Hcl | Metformin Hcl | 559 | 137 |
| Omeprazole | Omeprazole | 540 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 108 |
| Losartan Potassium | Losartan Potassium | 464 | 111 |
| Furosemide | Furosemide | 405 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 316 | 80 |
| Trazodone Hcl | Trazodone Hcl | 286 | 63 |
| Potassium Chloride | Potassium Chloride | 266 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 51 |
| Allopurinol | Allopurinol | 212 | 50 |
| Eliquis | Apixaban | 204 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 48 |
| Simvastatin | Simvastatin | 186 | 38 |
| Tramadol Hcl | Tramadol Hcl | 173 | 43 |
| Alprazolam | Alprazolam | 171 | 33 |
| Famotidine | Famotidine | 165 | 35 |
| Glimepiride | Glimepiride | 162 | 44 |
| Prednisone | Prednisone | 157 | 127 |
| Clonazepam | Clonazepam | 154 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 32 |
| Farxiga | Dapagliflozin Propanediol | 141 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 141 | 45 |
| Jardiance | Empagliflozin | 140 | 25 |
| Atenolol | Atenolol | 133 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 130 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 34 |
| Meloxicam | Meloxicam | 121 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 34 |
| Myrbetriq | Mirabegron | 116 | 19 |
| Baclofen | Baclofen | 110 | 16 |
| Lorazepam | Lorazepam | 110 | 36 |
| Glipizide Er | Glipizide | 109 | 22 |
| Ozempic | Semaglutide | 108 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 29 |
| Azithromycin | Azithromycin | 100 | 87 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 22 |
| Warfarin Sodium | Warfarin Sodium | 99 | 26 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 97 | 23 |
| Pregabalin | Pregabalin | 97 | 22 |
| Celecoxib | Celecoxib | 95 | 20 |
| Carvedilol | Carvedilol | 93 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 14 |
| Propranolol Hcl | Propranolol Hcl | 92 | 13 |
| Sertraline Hcl | Sertraline Hcl | 91 | 27 |
| Diazepam | Diazepam | 90 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 67 |
| Azelastine Hcl | Azelastine Hcl | 85 | 39 |
| Mounjaro | Tirzepatide | 85 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 22 |
| Metformin Hcl Er | Metformin Hcl | 80 | 17 |
| Lovastatin | Lovastatin | 79 | 16 |
| Clonidine Hcl | Clonidine Hcl | 78 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 65 |
| Meclizine Hcl | Meclizine Hcl | 74 | 25 |
| Benazepril Hcl | Benazepril Hcl | 73 | 21 |
| Montelukast Sodium | Montelukast Sodium | 73 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 15 |
| Chlorthalidone | Chlorthalidone | 68 | 17 |
| Valsartan | Valsartan | 67 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 15 |
| Alendronate Sodium | Alendronate Sodium | 60 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 17 |
| Spironolactone | Spironolactone | 60 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 45 |
| Topiramate | Topiramate | 60 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | 20 |
| Methocarbamol | Methocarbamol | 59 | 25 |
| Buspirone Hcl | Buspirone Hcl | 58 | 13 |
| Donepezil Hcl | Donepezil Hcl | 58 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | suppressed |
| Mirtazapine | Mirtazapine | 56 | 13 |
| Finasteride | Finasteride | 55 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | suppressed |
| Glipizide | Glipizide | 52 | 11 |
| Nystatin | Nystatin | 51 | 29 |
| Ibuprofen | Ibuprofen | 50 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | 11 |
| Bupropion Xl | Bupropion Hcl | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | 12 |
| Valacyclovir | Valacyclovir Hcl | 45 | 19 |
| Amoxicillin | Amoxicillin | 44 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 11 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Linzess | Linaclotide | 41 | 11 |
| Ramipril | Ramipril | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 38 |
| Estradiol | Estradiol | 36 | suppressed |
| Colchicine | Colchicine | 34 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 32 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Risperidone | Risperidone | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 16 |
| Naproxen | Naproxen | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 14 |
| Cilostazol | Cilostazol | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 14 |
| Modafinil | Modafinil | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,031.30 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, HETLIOZ, Haegarda, JARDIANCE, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, OCALIVA, QULIPTA, REBYOTA, REXULTI, SIMPONI, SIMPONI ARIA, STELARA, TRELEGY ELLIPTA, TREMFYA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error